Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study
The effectiveness of heterologous prime-boost Coronavirus disease 2019 (Covid-19) vaccination is currently unknown. From individuals vaccinated with two doses against Covid-19 in Sweden until July 5, 2021 (N=3,445,061), we formed a study cohort including 94,569 individuals that had received heterolo...
Saved in:
Published in | The Lancet regional health. Europe Vol. 11; p. 100249 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.12.2021
Elsevier |
Subjects | |
Online Access | Get full text |
ISSN | 2666-7762 2666-7762 |
DOI | 10.1016/j.lanepe.2021.100249 |
Cover
Abstract | The effectiveness of heterologous prime-boost Coronavirus disease 2019 (Covid-19) vaccination is currently unknown.
From individuals vaccinated with two doses against Covid-19 in Sweden until July 5, 2021 (N=3,445,061), we formed a study cohort including 94,569 individuals that had received heterologous ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination, 16,402 individuals that received heterologous ChAdOx1 nCoV-19 / mRNA-1273 prime-boost vaccination, and 430,100 individuals that received homologous ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19 prime-boost vaccination. In addition, 180,716 individuals were selected who were unvaccinated at the date of vaccination in the corresponding case. Unvaccinated individuals were censored at first dose of any vaccine. Baseline was the date of the second dose of any vaccine, with the same date in the corresponding unvaccinated individual. The outcome included incident symptomatic Covid-19 infection occurring >14 days after baseline.
During a mean follow-up time of 76 (range 1-183) days, symptomatic Covid-19 infection was confirmed in 187 individuals with heterologous vaccine schedules (incidence rate: 2.0/100,000 person-days) and in 306 individuals from the unvaccinated control group (incidence rate: 7.1/100,000 person-days). The adjusted vaccine effectiveness was 67% (95% CI, 59-73, P<0.001) for heterologous ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination, and 79% (95% CI, 62-88, P<0.001) for heterologous ChAdOx1 nCoV-19 / mRNA-1273 prime-boost vaccination. When combined and analysed together, the two heterologous vaccine schedules had an effectiveness of 68% (95% CI, 61-74, P<0.001) which was significantly greater (Pinteraction<0.001) than the 50% effectiveness for homologous ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19 (95% CI, 41-58, P<0.001).
The findings of this study suggest that the use of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination is an effective alternative to increase population immunity against Covid-19, including against the Delta variant which dominated the confirmed cases during the study period. These findings could have important implications for vaccination strategies and logistics, and consequently in the battle against the Covid-19 pandemic. |
---|---|
AbstractList | Background - The effectiveness of heterologous prime-boost Coronavirus disease 2019 (Covid-19) vaccination is currently unknown.
Methods - From individuals vaccinated with two doses against Covid-19 in Sweden until July 5, 2021 (N=3,445,061), we formed a study cohort including 94,569 individuals that had received heterologous ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination, 16,402 individuals that received heterologous ChAdOx1 nCoV-19 / mRNA-1273 prime-boost vaccination, and 430,100 individuals that received homologous ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19 prime-boost vaccination. In addition, 180,716 individuals were selected who were unvaccinated at the date of vaccination in the corresponding case. Unvaccinated individuals were censored at first dose of any vaccine. Baseline was the date of the second dose of any vaccine, with the same date in the corresponding unvaccinated individual. The outcome included incident symptomatic Covid-19 infection occurring >14 days after baseline.
Findings - During a mean follow-up time of 76 (range 1-183) days, symptomatic Covid-19 infection was confirmed in 187 individuals with heterologous vaccine schedules (incidence rate: 2.0/100,000 person-days) and in 306 individuals from the unvaccinated control group (incidence rate: 7.1/100,000 person-days). The adjusted vaccine effectiveness was 67% (95% CI, 59-73, P<0.001) for heterologous ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination, and 79% (95% CI, 62-88, P<0.001) for heterologous ChAdOx1 nCoV-19 / mRNA-1273 prime-boost vaccination. When combined and analysed together, the two heterologous vaccine schedules had an effectiveness of 68% (95% CI, 61-74, P<0.001) which was significantly greater (Pinteraction<0.001) than the 50% effectiveness for homologous ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19 (95% CI, 41-58, P<0.001).
Interpretation - The findings of this study suggest that the use of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination is an effective alternative to increase population immunity against Covid-19, including against the Delta variant which dominated the confirmed cases during the study period. These findings could have important implications for vaccination strategies and logistics, and consequently in the battle against the Covid-19 pandemic. SummaryBackgroundThe effectiveness of heterologous prime-boost Coronavirus disease 2019 (Covid-19) vaccination is currently unknown. MethodsFrom individuals vaccinated with two doses against Covid-19 in Sweden until July 5, 2021 (N=3,445,061), we formed a study cohort including 94,569 individuals that had received heterologous ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination, 16,402 individuals that received heterologous ChAdOx1 nCoV-19 / mRNA-1273 prime-boost vaccination, and 430,100 individuals that received homologous ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19 prime-boost vaccination. In addition, 180,716 individuals were selected who were unvaccinated at the date of vaccination in the corresponding case. Unvaccinated individuals were censored at first dose of any vaccine. Baseline was the date of the second dose of any vaccine, with the same date in the corresponding unvaccinated individual. The outcome included incident symptomatic Covid-19 infection occurring >14 days after baseline. FindingsDuring a mean follow-up time of 76 (range 1-183) days, symptomatic Covid-19 infection was confirmed in 187 individuals with heterologous vaccine schedules (incidence rate: 2.0/100,000 person-days) and in 306 individuals from the unvaccinated control group (incidence rate: 7.1/100,000 person-days). The adjusted vaccine effectiveness was 67% (95% CI, 59-73, P<0.001) for heterologous ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination, and 79% (95% CI, 62-88, P<0.001) for heterologous ChAdOx1 nCoV-19 / mRNA-1273 prime-boost vaccination. When combined and analysed together, the two heterologous vaccine schedules had an effectiveness of 68% (95% CI, 61-74, P<0.001) which was significantly greater (P interaction<0.001) than the 50% effectiveness for homologous ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19 (95% CI, 41-58, P<0.001). InterpretationThe findings of this study suggest that the use of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination is an effective alternative to increase population immunity against Covid-19, including against the Delta variant which dominated the confirmed cases during the study period. These findings could have important implications for vaccination strategies and logistics, and consequently in the battle against the Covid-19 pandemic. The effectiveness of heterologous prime-boost Coronavirus disease 2019 (Covid-19) vaccination is currently unknown.BACKGROUNDThe effectiveness of heterologous prime-boost Coronavirus disease 2019 (Covid-19) vaccination is currently unknown.From individuals vaccinated with two doses against Covid-19 in Sweden until July 5, 2021 (N=3,445,061), we formed a study cohort including 94,569 individuals that had received heterologous ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination, 16,402 individuals that received heterologous ChAdOx1 nCoV-19 / mRNA-1273 prime-boost vaccination, and 430,100 individuals that received homologous ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19 prime-boost vaccination. In addition, 180,716 individuals were selected who were unvaccinated at the date of vaccination in the corresponding case. Unvaccinated individuals were censored at first dose of any vaccine. Baseline was the date of the second dose of any vaccine, with the same date in the corresponding unvaccinated individual. The outcome included incident symptomatic Covid-19 infection occurring >14 days after baseline.METHODSFrom individuals vaccinated with two doses against Covid-19 in Sweden until July 5, 2021 (N=3,445,061), we formed a study cohort including 94,569 individuals that had received heterologous ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination, 16,402 individuals that received heterologous ChAdOx1 nCoV-19 / mRNA-1273 prime-boost vaccination, and 430,100 individuals that received homologous ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19 prime-boost vaccination. In addition, 180,716 individuals were selected who were unvaccinated at the date of vaccination in the corresponding case. Unvaccinated individuals were censored at first dose of any vaccine. Baseline was the date of the second dose of any vaccine, with the same date in the corresponding unvaccinated individual. The outcome included incident symptomatic Covid-19 infection occurring >14 days after baseline.During a mean follow-up time of 76 (range 1-183) days, symptomatic Covid-19 infection was confirmed in 187 individuals with heterologous vaccine schedules (incidence rate: 2.0/100,000 person-days) and in 306 individuals from the unvaccinated control group (incidence rate: 7.1/100,000 person-days). The adjusted vaccine effectiveness was 67% (95% CI, 59-73, P<0.001) for heterologous ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination, and 79% (95% CI, 62-88, P<0.001) for heterologous ChAdOx1 nCoV-19 / mRNA-1273 prime-boost vaccination. When combined and analysed together, the two heterologous vaccine schedules had an effectiveness of 68% (95% CI, 61-74, P<0.001) which was significantly greater (Pinteraction<0.001) than the 50% effectiveness for homologous ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19 (95% CI, 41-58, P<0.001).FINDINGSDuring a mean follow-up time of 76 (range 1-183) days, symptomatic Covid-19 infection was confirmed in 187 individuals with heterologous vaccine schedules (incidence rate: 2.0/100,000 person-days) and in 306 individuals from the unvaccinated control group (incidence rate: 7.1/100,000 person-days). The adjusted vaccine effectiveness was 67% (95% CI, 59-73, P<0.001) for heterologous ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination, and 79% (95% CI, 62-88, P<0.001) for heterologous ChAdOx1 nCoV-19 / mRNA-1273 prime-boost vaccination. When combined and analysed together, the two heterologous vaccine schedules had an effectiveness of 68% (95% CI, 61-74, P<0.001) which was significantly greater (Pinteraction<0.001) than the 50% effectiveness for homologous ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19 (95% CI, 41-58, P<0.001).The findings of this study suggest that the use of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination is an effective alternative to increase population immunity against Covid-19, including against the Delta variant which dominated the confirmed cases during the study period. These findings could have important implications for vaccination strategies and logistics, and consequently in the battle against the Covid-19 pandemic.INTERPRETATIONThe findings of this study suggest that the use of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination is an effective alternative to increase population immunity against Covid-19, including against the Delta variant which dominated the confirmed cases during the study period. These findings could have important implications for vaccination strategies and logistics, and consequently in the battle against the Covid-19 pandemic. The effectiveness of heterologous prime-boost Coronavirus disease 2019 (Covid-19) vaccination is currently unknown. From individuals vaccinated with two doses against Covid-19 in Sweden until July 5, 2021 (N=3,445,061), we formed a study cohort including 94,569 individuals that had received heterologous ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination, 16,402 individuals that received heterologous ChAdOx1 nCoV-19 / mRNA-1273 prime-boost vaccination, and 430,100 individuals that received homologous ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19 prime-boost vaccination. In addition, 180,716 individuals were selected who were unvaccinated at the date of vaccination in the corresponding case. Unvaccinated individuals were censored at first dose of any vaccine. Baseline was the date of the second dose of any vaccine, with the same date in the corresponding unvaccinated individual. The outcome included incident symptomatic Covid-19 infection occurring >14 days after baseline. During a mean follow-up time of 76 (range 1-183) days, symptomatic Covid-19 infection was confirmed in 187 individuals with heterologous vaccine schedules (incidence rate: 2.0/100,000 person-days) and in 306 individuals from the unvaccinated control group (incidence rate: 7.1/100,000 person-days). The adjusted vaccine effectiveness was 67% (95% CI, 59-73, P<0.001) for heterologous ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination, and 79% (95% CI, 62-88, P<0.001) for heterologous ChAdOx1 nCoV-19 / mRNA-1273 prime-boost vaccination. When combined and analysed together, the two heterologous vaccine schedules had an effectiveness of 68% (95% CI, 61-74, P<0.001) which was significantly greater (Pinteraction<0.001) than the 50% effectiveness for homologous ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19 (95% CI, 41-58, P<0.001). The findings of this study suggest that the use of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination is an effective alternative to increase population immunity against Covid-19, including against the Delta variant which dominated the confirmed cases during the study period. These findings could have important implications for vaccination strategies and logistics, and consequently in the battle against the Covid-19 pandemic. The effectiveness of heterologous prime-boost Coronavirus disease 2019 (Covid-19) vaccination is currently unknown. From individuals vaccinated with two doses against Covid-19 in Sweden until July 5, 2021 (N=3,445,061), we formed a study cohort including 94,569 individuals that had received heterologous ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination, 16,402 individuals that received heterologous ChAdOx1 nCoV-19 / mRNA-1273 prime-boost vaccination, and 430,100 individuals that received homologous ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19 prime-boost vaccination. In addition, 180,716 individuals were selected who were unvaccinated at the date of vaccination in the corresponding case. Unvaccinated individuals were censored at first dose of any vaccine. Baseline was the date of the second dose of any vaccine, with the same date in the corresponding unvaccinated individual. The outcome included incident symptomatic Covid-19 infection occurring >14 days after baseline. During a mean follow-up time of 76 (range 1-183) days, symptomatic Covid-19 infection was confirmed in 187 individuals with heterologous vaccine schedules (incidence rate: 2.0/100,000 person-days) and in 306 individuals from the unvaccinated control group (incidence rate: 7.1/100,000 person-days). The adjusted vaccine effectiveness was 67% (95% CI, 59-73, P<0.001) for heterologous ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination, and 79% (95% CI, 62-88, P<0.001) for heterologous ChAdOx1 nCoV-19 / mRNA-1273 prime-boost vaccination. When combined and analysed together, the two heterologous vaccine schedules had an effectiveness of 68% (95% CI, 61-74, P<0.001) which was significantly greater (P <0.001) than the 50% effectiveness for homologous ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19 (95% CI, 41-58, P<0.001). The findings of this study suggest that the use of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination is an effective alternative to increase population immunity against Covid-19, including against the Delta variant which dominated the confirmed cases during the study period. These findings could have important implications for vaccination strategies and logistics, and consequently in the battle against the Covid-19 pandemic. Background: The effectiveness of heterologous prime-boost Coronavirus disease 2019 (Covid-19) vaccination is currently unknown. Methods: From individuals vaccinated with two doses against Covid-19 in Sweden until July 5, 2021 (N=3,445,061), we formed a study cohort including 94,569 individuals that had received heterologous ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination, 16,402 individuals that received heterologous ChAdOx1 nCoV-19 / mRNA-1273 prime-boost vaccination, and 430,100 individuals that received homologous ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19 prime-boost vaccination. In addition, 180,716 individuals were selected who were unvaccinated at the date of vaccination in the corresponding case. Unvaccinated individuals were censored at first dose of any vaccine. Baseline was the date of the second dose of any vaccine, with the same date in the corresponding unvaccinated individual. The outcome included incident symptomatic Covid-19 infection occurring >14 days after baseline. Findings: During a mean follow-up time of 76 (range 1-183) days, symptomatic Covid-19 infection was confirmed in 187 individuals with heterologous vaccine schedules (incidence rate: 2.0/100,000 person-days) and in 306 individuals from the unvaccinated control group (incidence rate: 7.1/100,000 person-days). The adjusted vaccine effectiveness was 67% (95% CI, 59-73, P<0.001) for heterologous ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination, and 79% (95% CI, 62-88, P<0.001) for heterologous ChAdOx1 nCoV-19 / mRNA-1273 prime-boost vaccination. When combined and analysed together, the two heterologous vaccine schedules had an effectiveness of 68% (95% CI, 61-74, P<0.001) which was significantly greater (P interaction <0.001) than the 50% effectiveness for homologous ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19 (95% CI, 41-58, P<0.001). Interpretation: The findings of this study suggest that the use of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination is an effective alternative to increase population immunity against Covid-19, including against the Delta variant which dominated the confirmed cases during the study period. These findings could have important implications for vaccination strategies and logistics, and consequently in the battle against the Covid-19 pandemic. Background: The effectiveness of heterologous prime-boost Coronavirus disease 2019 (Covid-19) vaccination is currently unknown. Methods: From individuals vaccinated with two doses against Covid-19 in Sweden until July 5, 2021 (N=3,445,061), we formed a study cohort including 94,569 individuals that had received heterologous ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination, 16,402 individuals that received heterologous ChAdOx1 nCoV-19 / mRNA-1273 prime-boost vaccination, and 430,100 individuals that received homologous ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19 prime-boost vaccination. In addition, 180,716 individuals were selected who were unvaccinated at the date of vaccination in the corresponding case. Unvaccinated individuals were censored at first dose of any vaccine. Baseline was the date of the second dose of any vaccine, with the same date in the corresponding unvaccinated individual. The outcome included incident symptomatic Covid-19 infection occurring >14 days after baseline. Findings: During a mean follow-up time of 76 (range 1-183) days, symptomatic Covid-19 infection was confirmed in 187 individuals with heterologous vaccine schedules (incidence rate: 2.0/100,000 person-days) and in 306 individuals from the unvaccinated control group (incidence rate: 7.1/100,000 person-days). The adjusted vaccine effectiveness was 67% (95% CI, 59-73, P<0.001) for heterologous ChAdOx1 nCoV-19 / BNT162b2 prime-boost vaccination, and 79% (95% CI, 62-88, P<0.001) for heterologous ChAdOx1 nCoV-19 / mRNA-1273 prime-boost vaccination. When combined and analysed together, the two heterologous vaccine schedules had an effectiveness of 68% (95% CI, 61-74, P<0.001) which was significantly greater (Pinteraction<0.001) than the 50% effectiveness for homologous ChAdOx1 nCoV-19 / ChAdOx1 nCoV-19 (95% CI, 41-58, P<0.001). Interpretation: The findings of this study suggest that the use of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination is an effective alternative to increase population immunity against Covid-19, including against the Delta variant which dominated the confirmed cases during the study period. These findings could have important implications for vaccination strategies and logistics, and consequently in the battle against the Covid-19 pandemic. |
ArticleNumber | 100249 |
Author | Ballin, Marcel Nordström, Anna Nordström, Peter |
Author_xml | – sequence: 1 givenname: Peter orcidid: 0000-0003-2924-508X surname: Nordström fullname: Nordström, Peter email: peter.nordstrom@umu.se organization: Department of Community Medicine and Rehabilitation, Unit of Geriatric Medicine, Umeå University, Umeå, Sweden (Peter Nordström and Marcel Ballin) – sequence: 2 givenname: Marcel surname: Ballin fullname: Ballin, Marcel organization: Department of Community Medicine and Rehabilitation, Unit of Geriatric Medicine, Umeå University, Umeå, Sweden (Peter Nordström and Marcel Ballin) – sequence: 3 givenname: Anna surname: Nordström fullname: Nordström, Anna organization: Department of Public Health and Clinical Medicine, Section of Sustainable Health, Umeå University, Umeå, Sweden (Marcel Ballin and Anna Nordström) |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34693387$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-190148$$DView record from Swedish Publication Index |
BookMark | eNqVU91u0zAUjtAQG2NvgMCX3KTETuIkE0KqyoBJE5MY7NZy7OPWJbGLnbT0VXhanKabViQ0cZXo-PvxOefz8-jIWANR9BInE5xg-nY5abiBFUxIQnAoJSSrnkQnhFIaFwUlRw_-j6Mz75dJwOQ4JTh7Fh2nGa3StCxOot8XSoHo9BoMeI-sQgvowNnGzm3v0Wwxlde_MDIzexvjCnEjUfv1yxStnG4hrq31HVpzIbThnbYG8TnXJtT8tl11tg1FgWZ2reXA1mbnFWDaoJsNSDDnaIpG6kZLQMIurAvsrpfbF9FTxRsPZ_vvafT948W32ef46vrT5Wx6FQtaVV1cZqA4xWmhSMZpSfOMKpJTKaEQGc7LvKqVpIkAqWgqVVLUZQF1KuqSEl5hnJ5Gl6OutHzJhsa42zLLNdsVrJsz7kIfDTBJalLjOse4UFkFosYQnBTUGAe7nAateNTyG1j19YHaB3073an1bc9wleCsDPj3Iz6AW5ACTOd4c0A7PDF6weZ2zcqcJCUeBF6PAsJp32nDjHWchUCkBSNpUSQB8WZv4ezPHnzHWu0FNEOAwooZGUZEyormAfrq4W3ur3EXlwDI7tys9w7UPQQnbAgmW7IxmGwIJhuDGWjnf9GE7nZLDz3p5jHyfkQQMrDW4JgXGkzYp3YhTWFJ-n8FRKONFrz5AVvwS9s7E_LFMPOEJexmeDjDuyEDP82HCb77t8Dj_n8AtusqvQ |
CitedBy_id | crossref_primary_10_3947_ic_2022_0132 crossref_primary_10_1016_j_lansea_2023_100141 crossref_primary_10_3390_vaccines10111869 crossref_primary_10_1016_j_ebiom_2021_103761 crossref_primary_10_1007_s40261_022_01195_x crossref_primary_10_1038_s41467_022_32321_0 crossref_primary_10_1017_ash_2021_261 crossref_primary_10_1038_s41467_023_35949_8 crossref_primary_10_3389_fmicb_2022_856913 crossref_primary_10_3389_fimmu_2024_1406138 crossref_primary_10_1186_s12879_022_07814_4 crossref_primary_10_1099_acmi_0_000513_v3 crossref_primary_10_3389_fimmu_2022_910136 crossref_primary_10_1007_s00284_024_03689_7 crossref_primary_10_3390_vaccines10071080 crossref_primary_10_1007_s40620_022_01247_7 crossref_primary_10_3899_jrheum_220469 crossref_primary_10_1084_jem_20220826 crossref_primary_10_1093_cid_ciac446 crossref_primary_10_1016_j_imlet_2022_09_001 crossref_primary_10_1080_14760584_2024_2315089 crossref_primary_10_1126_science_abn2688 crossref_primary_10_1038_s41467_022_29301_9 crossref_primary_10_1371_journal_pone_0265159 crossref_primary_10_3390_jpm14040358 crossref_primary_10_1016_j_ijdrr_2022_103233 crossref_primary_10_1038_s41541_022_00531_8 crossref_primary_10_1016_S0140_6736_21_02718_5 crossref_primary_10_1093_ofid_ofac138 crossref_primary_10_3389_fpubh_2022_873596 crossref_primary_10_1371_journal_pone_0285737 crossref_primary_10_1136_bmj_2022_069989 crossref_primary_10_1172_JCI157707 crossref_primary_10_3389_fcimb_2023_1297078 crossref_primary_10_1128_spectrum_00609_22 crossref_primary_10_3390_diseases10020025 crossref_primary_10_1080_21645515_2022_2052525 crossref_primary_10_1016_j_vaccine_2021_12_032 crossref_primary_10_1080_00365521_2022_2114809 crossref_primary_10_3390_diagnostics14242850 crossref_primary_10_1038_s41385_022_00517_8 crossref_primary_10_1038_s41392_022_00984_2 crossref_primary_10_3390_tropicalmed7050081 crossref_primary_10_1371_journal_pone_0273903 crossref_primary_10_1016_j_vaccine_2022_10_011 crossref_primary_10_3389_fimmu_2023_1107803 crossref_primary_10_1038_d41586_021_02853_4 crossref_primary_10_1371_journal_ppat_1010885 crossref_primary_10_1093_bmb_ldac025 crossref_primary_10_1371_journal_pone_0263861 crossref_primary_10_1016_j_vaccine_2022_09_007 crossref_primary_10_1002_jmv_27749 crossref_primary_10_1080_21645515_2022_2153532 crossref_primary_10_1098_rsif_2024_0445 crossref_primary_10_1080_22221751_2022_2048969 crossref_primary_10_1136_bmj_2022_070483 crossref_primary_10_1371_journal_pgph_0003260 crossref_primary_10_1038_s41392_024_01751_1 crossref_primary_10_3389_fmed_2022_994160 crossref_primary_10_1016_S0140_6736_21_02717_3 crossref_primary_10_3390_vaccines10070984 crossref_primary_10_1080_23744235_2022_2080250 crossref_primary_10_1016_j_jclinepi_2022_11_007 crossref_primary_10_1177_08903344221103260 crossref_primary_10_3201_eid2810_221134 crossref_primary_10_3389_fimmu_2022_945930 crossref_primary_10_1080_21645515_2023_2209919 crossref_primary_10_1146_annurev_immunol_101721_061120 crossref_primary_10_3389_fimmu_2022_882918 crossref_primary_10_1038_s41467_022_33146_7 crossref_primary_10_1016_j_ymthe_2022_04_016 crossref_primary_10_3390_vaccines10030359 crossref_primary_10_3390_v15030751 crossref_primary_10_1186_s12916_022_02480_4 |
Cites_doi | 10.1001/jama.2021.8565 10.1016/S0140-6736(21)01442-2 10.1016/S0140-6736(21)01694-9 10.1016/S0140-6736(21)01420-3 10.1136/bmj.n1114 10.1016/S0140-6736(20)32661-1 10.1056/NEJMoa2034577 10.1056/NEJMc2110716 10.1038/s41591-021-01446-y 10.1056/NEJMoa2101765 10.1016/S0140-6736(21)00947-8 10.1016/S1473-3099(21)00420-5 10.1016/S0140-6736(21)01115-6 10.1056/NEJMc2104974 10.1136/bmj.n1943 10.1056/NEJMoa2035389 10.1007/s10654-021-00732-w 10.1056/NEJMoa2101544 10.1016/S0140-6736(21)00677-2 10.15585/mmwr.mm7013e3 10.1016/S2213-2600(21)00357-X |
ContentType | Journal Article |
Copyright | 2021 The Author(s) The Author(s) 2021 The Author(s). info:eu-repo/semantics/openAccess 2021 The Author(s) 2021 |
Copyright_xml | – notice: 2021 The Author(s) – notice: The Author(s) – notice: 2021 The Author(s). – notice: info:eu-repo/semantics/openAccess – notice: 2021 The Author(s) 2021 |
DBID | 6I. AAFTH AAYXX CITATION NPM 7X8 3HK 5PM ADHXS ADTPV AOWAS D8T D93 ZZAVC DOA |
DOI | 10.1016/j.lanepe.2021.100249 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed MEDLINE - Academic NORA - Norwegian Open Research Archives PubMed Central (Full Participant titles) SWEPUB Umeå universitet full text SwePub SwePub Articles SWEPUB Freely available online SWEPUB Umeå universitet SwePub Articles full text DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Public Health |
EISSN | 2666-7762 |
EndPage | 100249 |
ExternalDocumentID | oai_doaj_org_article_d2b2b1b5117f49ecb1e56dfeb11de756 oai_DiVA_org_umu_190148 PMC8520818 10037_23770 34693387 10_1016_j_lanepe_2021_100249 S2666776221002350 1_s2_0_S2666776221002350 |
Genre | Journal Article |
GroupedDBID | .1- .FO 0R~ 53G AAEDW AALRI AAMRU AAXUO ACVFH ADCNI AEUPX AFPUW AFRHN AIGII AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS APXCP FDB GROUPED_DOAJ M~E OK1 ROL RPM Z5R AAHOK 6I. AAFTH AAYXX CITATION NPM 7X8 3HK 5PM ADHXS ADTPV AOWAS D8T D93 ZZAVC |
ID | FETCH-LOGICAL-c699t-84efa6137f24a686546f256dde7c415859bfd60cedf63df07b87eb3cb862a9113 |
IEDL.DBID | DOA |
ISSN | 2666-7762 |
IngestDate | Wed Aug 27 01:17:34 EDT 2025 Thu Aug 21 06:44:16 EDT 2025 Thu Aug 21 18:32:37 EDT 2025 Tue May 06 06:43:35 EDT 2025 Fri Jul 11 08:52:23 EDT 2025 Mon Jul 21 06:05:34 EDT 2025 Tue Jul 01 04:25:14 EDT 2025 Thu Apr 24 23:08:40 EDT 2025 Tue Jul 25 21:00:47 EDT 2023 Sun Feb 23 10:18:41 EST 2025 Tue Aug 26 16:32:07 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Language | English |
License | This is an open access article under the CC BY-NC-ND license. https://www.elsevier.com/tdm/userlicense/1.0 http://creativecommons.org/licenses/by-nc-nd/4.0 2021 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c699t-84efa6137f24a686546f256dde7c415859bfd60cedf63df07b87eb3cb862a9113 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 The Lancet Regional Health - Europe |
ORCID | 0000-0003-2924-508X |
OpenAccessLink | https://doaj.org/article/d2b2b1b5117f49ecb1e56dfeb11de756 |
PMID | 34693387 |
PQID | 2585928965 |
PQPubID | 23479 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_d2b2b1b5117f49ecb1e56dfeb11de756 swepub_primary_oai_DiVA_org_umu_190148 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8520818 cristin_nora_10037_23770 proquest_miscellaneous_2585928965 pubmed_primary_34693387 crossref_primary_10_1016_j_lanepe_2021_100249 crossref_citationtrail_10_1016_j_lanepe_2021_100249 elsevier_sciencedirect_doi_10_1016_j_lanepe_2021_100249 elsevier_clinicalkeyesjournals_1_s2_0_S2666776221002350 elsevier_clinicalkey_doi_10_1016_j_lanepe_2021_100249 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2021-12-01 |
PublicationDateYYYYMMDD | 2021-12-01 |
PublicationDate_xml | – month: 12 year: 2021 text: 2021-12-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | The Lancet regional health. Europe |
PublicationTitleAlternate | Lancet Reg Health Eur |
PublicationYear | 2021 |
Publisher | Elsevier Ltd Elsevier |
Publisher_xml | – name: Elsevier Ltd – name: Elsevier |
References | Voysey, Clemens, Madhi (bib0002) 2021; 397 Chemaitelly, Yassine, Benslimane (bib0011) 2021 European Centre for Disease Prevention and Control. Overview of EU/EEA country recommendations on COVID-19 vaccination with Vaxzevria, and a scoping review of evidence to guide decision-making. May 18, 2021. Available from Normark, Vikström, Gwon (bib0020) 2021 Baden, El Sahly, Essink (bib0004) 2021; 384 Haas, Angulo, McLaughlin (bib0009) 2021; 397 Public Health Agency of Sweden. SmiNet. Available from World Health Organization. WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access. December 30, 2020. Available from Borobia, Carcas, Perez-Olmeda (bib0019) 2021; 398 Accessed 17 June, 2021. Bergman, Ballin, Nordstrom, Nordstrom (bib0031) 2021; 36 Public Health Agency of Sweden. Recommendation for an age limit of 65 for AstraZeneca's vaccine remains. April 20, 2021. Available from Accessed 16 June, 2021. Vasileiou, Simpson, Shi (bib0008) 2021; 397 Chung, He, Nasreen (bib0010) 2021; 374 Groß, Zanoni, Seidel (bib0024) 2021 Shaw, Stuart, Greenland (bib0025) 2021; 397 Accessed June 22, 2021. The Statistics Sweden Database. The official agency for goverment statistics. Sweden. Available at Accessed 27 July, 2021. Hillus, Schwarz, Tober-Lau (bib0022) 2021 Abu-Raddad, Chemaitelly, Butt (bib0032) 2021; 385 World Health Organization. Evaluation of COVID-19 vaccine effectiveness. Interim guidance. March 17, 2021. Available from Public Health Agency of Sweden. Statistics on SARS-CoV-2 variants of concern. 2021. Available from Tenbusch, Schumacher, Vogel (bib0021) 2021; 21 Polack, Thomas, Kitchin (bib0003) 2020; 383 European Medicines Agency. AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. April 7, 2021. Available from Dagan, Barda, Kepten (bib0007) 2021; 384 . Thompson, Burgess, Naleway (bib0012) 2021; 70 Public Health Agency of Sweden. The National Vaccination Register. Available from Sadoff, Gray, Vandebosch (bib0005) 2021; 384 Barros-Martins, Hammerschmidt, Cossmann (bib0023) 2021 Duarte-Salles, Prieto-Alhambra (bib0026) 2021; 398 Pottegard, Lund, Karlstad (bib0014) 2021; 373 Al Kaabi, Zhang, Xia (bib0006) 2021; 326 Accessed June 22, 2021. . Wise (bib0016) 2021 Public Health Agency of Sweden. AstraZeneca vaccine paused as a precautionary measure pending EMA investigation. March 16, 2021. Available from Liu, Shaw, Stuart (bib0033) August 6, 2021 Al Kaabi (10.1016/j.lanepe.2021.100249_bib0006) 2021; 326 Chemaitelly (10.1016/j.lanepe.2021.100249_bib0011) 2021 Voysey (10.1016/j.lanepe.2021.100249_bib0002) 2021; 397 Shaw (10.1016/j.lanepe.2021.100249_bib0025) 2021; 397 Bergman (10.1016/j.lanepe.2021.100249_bib0031) 2021; 36 10.1016/j.lanepe.2021.100249_bib0028 Vasileiou (10.1016/j.lanepe.2021.100249_bib0008) 2021; 397 10.1016/j.lanepe.2021.100249_bib0029 10.1016/j.lanepe.2021.100249_bib0027 Baden (10.1016/j.lanepe.2021.100249_bib0004) 2021; 384 10.1016/j.lanepe.2021.100249_bib0001 Borobia (10.1016/j.lanepe.2021.100249_bib0019) 2021; 398 Polack (10.1016/j.lanepe.2021.100249_bib0003) 2020; 383 Liu (10.1016/j.lanepe.2021.100249_bib0033) 2021 Dagan (10.1016/j.lanepe.2021.100249_bib0007) 2021; 384 Normark (10.1016/j.lanepe.2021.100249_bib0020) 2021 Duarte-Salles (10.1016/j.lanepe.2021.100249_bib0026) 2021; 398 Tenbusch (10.1016/j.lanepe.2021.100249_bib0021) 2021; 21 Barros-Martins (10.1016/j.lanepe.2021.100249_bib0023) 2021 Thompson (10.1016/j.lanepe.2021.100249_bib0012) 2021; 70 Groß (10.1016/j.lanepe.2021.100249_bib0024) 2021 Wise (10.1016/j.lanepe.2021.100249_bib0016) 2021 Sadoff (10.1016/j.lanepe.2021.100249_bib0005) 2021; 384 10.1016/j.lanepe.2021.100249_bib0017 10.1016/j.lanepe.2021.100249_bib0018 10.1016/j.lanepe.2021.100249_bib0015 Chung (10.1016/j.lanepe.2021.100249_bib0010) 2021; 374 10.1016/j.lanepe.2021.100249_bib0013 Haas (10.1016/j.lanepe.2021.100249_bib0009) 2021; 397 10.1016/j.lanepe.2021.100249_bib0034 Pottegard (10.1016/j.lanepe.2021.100249_bib0014) 2021; 373 Hillus (10.1016/j.lanepe.2021.100249_bib0022) 2021 10.1016/j.lanepe.2021.100249_bib0030 Abu-Raddad (10.1016/j.lanepe.2021.100249_bib0032) 2021; 385 |
References_xml | – reference: The Statistics Sweden Database. The official agency for goverment statistics. Sweden. Available at: – reference: . Accessed 17 June, 2021. – year: 2021 ident: bib0011 article-title: mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar publication-title: Nat Med – reference: Public Health Agency of Sweden. AstraZeneca vaccine paused as a precautionary measure pending EMA investigation. March 16, 2021. Available from: – volume: 373 start-page: n1114 year: 2021 ident: bib0014 article-title: Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study publication-title: BMJ – reference: Public Health Agency of Sweden. SmiNet. Available from: – reference: Public Health Agency of Sweden. Statistics on SARS-CoV-2 variants of concern. 2021. Available from: – reference: European Centre for Disease Prevention and Control. Overview of EU/EEA country recommendations on COVID-19 vaccination with Vaxzevria, and a scoping review of evidence to guide decision-making. May 18, 2021. Available from: – volume: 398 start-page: 94 year: 2021 end-page: 95 ident: bib0026 article-title: Heterologous vaccine regimens against COVID-19 publication-title: Lancet – volume: 36 start-page: 287 year: 2021 end-page: 298 ident: bib0031 article-title: Risk factors for COVID-19 diagnosis, hospitalization, and subsequent all-cause mortality in Sweden: a nationwide study publication-title: Eur J Epidemiol – volume: 398 start-page: 121 year: 2021 end-page: 130 ident: bib0019 article-title: Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial publication-title: Lancet – volume: 21 start-page: 1212 year: 2021 end-page: 1213 ident: bib0021 article-title: Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 publication-title: Lancet Infect Dis – reference: World Health Organization. Evaluation of COVID-19 vaccine effectiveness. Interim guidance. March 17, 2021. Available from: – volume: 397 start-page: 1819 year: 2021 end-page: 1829 ident: bib0009 article-title: Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data publication-title: The Lancet – start-page: 372 year: 2021 ident: bib0016 article-title: Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots publication-title: Bmj-Brit Med J – volume: 385 start-page: 187 year: 2021 end-page: 189 ident: bib0032 article-title: Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants publication-title: New England Journal of Medicine – year: August 6, 2021 ident: bib0033 article-title: Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial publication-title: Lancet – year: 2021 ident: bib0024 article-title: Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity publication-title: medRxiv – year: 2021 ident: bib0020 article-title: Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination publication-title: New England Journal of Medicine – volume: 70 start-page: 495 year: 2021 end-page: 500 ident: bib0012 article-title: Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021 publication-title: MMWR Morb Mortal Wkly Rep – reference: European Medicines Agency. AstraZeneca's COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. April 7, 2021. Available from: – reference: . Accessed June 22, 2021. – volume: 384 start-page: 2187 year: 2021 end-page: 2201 ident: bib0005 article-title: Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 publication-title: N Engl J Med – reference: World Health Organization. WHO issues its first emergency use validation for a COVID-19 vaccine and emphasizes need for equitable global access. December 30, 2020. Available from: – reference: . – reference: Accessed 27 July, 2021. – reference: . Accessed 16 June, 2021. – reference: Public Health Agency of Sweden. The National Vaccination Register. Available from: – volume: 383 start-page: 2603 year: 2020 end-page: 2615 ident: bib0003 article-title: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine publication-title: N Engl J Med – volume: 384 start-page: 403 year: 2021 end-page: 416 ident: bib0004 article-title: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine publication-title: N Engl J Med – reference: Public Health Agency of Sweden. Recommendation for an age limit of 65 for AstraZeneca's vaccine remains. April 20, 2021. Available from: – year: 2021 ident: bib0022 article-title: Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study publication-title: Lancet Respir Med – volume: 384 start-page: 1412 year: 2021 end-page: 1423 ident: bib0007 article-title: BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting publication-title: N Engl J Med – year: 2021 ident: bib0023 article-title: Humoral and cellular immune response against SARS-CoV-2 variants following heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination publication-title: medRxiv – volume: 397 start-page: 1646 year: 2021 end-page: 1657 ident: bib0008 article-title: Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study publication-title: Lancet – volume: 374 start-page: n1943 year: 2021 ident: bib0010 article-title: Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study publication-title: BMJ – volume: 326 start-page: 35 year: 2021 end-page: 45 ident: bib0006 article-title: Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial publication-title: JAMA – volume: 397 start-page: 2043 year: 2021 end-page: 2046 ident: bib0025 article-title: Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data publication-title: Lancet – reference: . Accessed June 22, 2021. . – volume: 397 start-page: 99 year: 2021 end-page: 111 ident: bib0002 article-title: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK publication-title: Lancet – volume: 326 start-page: 35 issue: 1 year: 2021 ident: 10.1016/j.lanepe.2021.100249_bib0006 article-title: Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial publication-title: JAMA doi: 10.1001/jama.2021.8565 – ident: 10.1016/j.lanepe.2021.100249_bib0028 – ident: 10.1016/j.lanepe.2021.100249_bib0030 – ident: 10.1016/j.lanepe.2021.100249_bib0001 – volume: 398 start-page: 94 issue: 10295 year: 2021 ident: 10.1016/j.lanepe.2021.100249_bib0026 article-title: Heterologous vaccine regimens against COVID-19 publication-title: Lancet doi: 10.1016/S0140-6736(21)01442-2 – year: 2021 ident: 10.1016/j.lanepe.2021.100249_bib0033 article-title: Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial publication-title: Lancet doi: 10.1016/S0140-6736(21)01694-9 – volume: 398 start-page: 121 issue: 10295 year: 2021 ident: 10.1016/j.lanepe.2021.100249_bib0019 article-title: Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial publication-title: Lancet doi: 10.1016/S0140-6736(21)01420-3 – year: 2021 ident: 10.1016/j.lanepe.2021.100249_bib0024 article-title: Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity publication-title: medRxiv – ident: 10.1016/j.lanepe.2021.100249_bib0034 – volume: 373 start-page: n1114 year: 2021 ident: 10.1016/j.lanepe.2021.100249_bib0014 article-title: Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study publication-title: BMJ doi: 10.1136/bmj.n1114 – ident: 10.1016/j.lanepe.2021.100249_bib0015 – volume: 397 start-page: 99 issue: 10269 year: 2021 ident: 10.1016/j.lanepe.2021.100249_bib0002 article-title: Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK publication-title: Lancet doi: 10.1016/S0140-6736(20)32661-1 – ident: 10.1016/j.lanepe.2021.100249_bib0017 – ident: 10.1016/j.lanepe.2021.100249_bib0013 – volume: 383 start-page: 2603 issue: 27 year: 2020 ident: 10.1016/j.lanepe.2021.100249_bib0003 article-title: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine publication-title: N Engl J Med doi: 10.1056/NEJMoa2034577 – year: 2021 ident: 10.1016/j.lanepe.2021.100249_bib0020 article-title: Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination publication-title: New England Journal of Medicine doi: 10.1056/NEJMc2110716 – year: 2021 ident: 10.1016/j.lanepe.2021.100249_bib0011 article-title: mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar publication-title: Nat Med doi: 10.1038/s41591-021-01446-y – ident: 10.1016/j.lanepe.2021.100249_bib0029 – volume: 384 start-page: 1412 issue: 15 year: 2021 ident: 10.1016/j.lanepe.2021.100249_bib0007 article-title: BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting publication-title: N Engl J Med doi: 10.1056/NEJMoa2101765 – ident: 10.1016/j.lanepe.2021.100249_bib0027 – volume: 397 start-page: 1819 issue: 10287 year: 2021 ident: 10.1016/j.lanepe.2021.100249_bib0009 article-title: Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data publication-title: The Lancet doi: 10.1016/S0140-6736(21)00947-8 – volume: 21 start-page: 1212 issue: 9 year: 2021 ident: 10.1016/j.lanepe.2021.100249_bib0021 article-title: Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(21)00420-5 – volume: 397 start-page: 2043 issue: 10289 year: 2021 ident: 10.1016/j.lanepe.2021.100249_bib0025 article-title: Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data publication-title: Lancet doi: 10.1016/S0140-6736(21)01115-6 – volume: 385 start-page: 187 issue: 2 year: 2021 ident: 10.1016/j.lanepe.2021.100249_bib0032 article-title: Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants publication-title: New England Journal of Medicine doi: 10.1056/NEJMc2104974 – volume: 374 start-page: n1943 year: 2021 ident: 10.1016/j.lanepe.2021.100249_bib0010 article-title: Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study publication-title: BMJ doi: 10.1136/bmj.n1943 – volume: 384 start-page: 403 issue: 5 year: 2021 ident: 10.1016/j.lanepe.2021.100249_bib0004 article-title: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine publication-title: N Engl J Med doi: 10.1056/NEJMoa2035389 – ident: 10.1016/j.lanepe.2021.100249_bib0018 – volume: 36 start-page: 287 issue: 3 year: 2021 ident: 10.1016/j.lanepe.2021.100249_bib0031 article-title: Risk factors for COVID-19 diagnosis, hospitalization, and subsequent all-cause mortality in Sweden: a nationwide study publication-title: Eur J Epidemiol doi: 10.1007/s10654-021-00732-w – start-page: 372 year: 2021 ident: 10.1016/j.lanepe.2021.100249_bib0016 article-title: Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots publication-title: Bmj-Brit Med J – year: 2021 ident: 10.1016/j.lanepe.2021.100249_bib0023 article-title: Humoral and cellular immune response against SARS-CoV-2 variants following heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination publication-title: medRxiv – volume: 384 start-page: 2187 issue: 23 year: 2021 ident: 10.1016/j.lanepe.2021.100249_bib0005 article-title: Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2101544 – volume: 397 start-page: 1646 issue: 10285 year: 2021 ident: 10.1016/j.lanepe.2021.100249_bib0008 article-title: Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study publication-title: Lancet doi: 10.1016/S0140-6736(21)00677-2 – volume: 70 start-page: 495 year: 2021 ident: 10.1016/j.lanepe.2021.100249_bib0012 publication-title: MMWR Morb Mortal Wkly Rep doi: 10.15585/mmwr.mm7013e3 – year: 2021 ident: 10.1016/j.lanepe.2021.100249_bib0022 article-title: Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(21)00357-X |
SSID | ssj0002513214 |
Score | 2.5272803 |
Snippet | The effectiveness of heterologous prime-boost Coronavirus disease 2019 (Covid-19) vaccination is currently unknown.
From individuals vaccinated with two doses... SummaryBackgroundThe effectiveness of heterologous prime-boost Coronavirus disease 2019 (Covid-19) vaccination is currently unknown. MethodsFrom individuals... The effectiveness of heterologous prime-boost Coronavirus disease 2019 (Covid-19) vaccination is currently unknown.BACKGROUNDThe effectiveness of heterologous... Background - The effectiveness of heterologous prime-boost Coronavirus disease 2019 (Covid-19) vaccination is currently unknown. Methods - From individuals... Background: The effectiveness of heterologous prime-boost Coronavirus disease 2019 (Covid-19) vaccination is currently unknown. Methods: From individuals... Background: The effectiveness of heterologous prime-boost Coronavirus disease 2019 (Covid-19) vaccination is currently unknown. Methods: From individuals... |
SourceID | doaj swepub pubmedcentral cristin proquest pubmed crossref elsevier |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 100249 |
SubjectTerms | immunologi Immunology Internal Medicine Public Health Research Paper |
Title | Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2666776221002350 https://www.clinicalkey.es/playcontent/1-s2.0-S2666776221002350 https://dx.doi.org/10.1016/j.lanepe.2021.100249 https://www.ncbi.nlm.nih.gov/pubmed/34693387 https://www.proquest.com/docview/2585928965 http://hdl.handle.net/10037/23770 https://pubmed.ncbi.nlm.nih.gov/PMC8520818 https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-190148 https://doaj.org/article/d2b2b1b5117f49ecb1e56dfeb11de756 |
Volume | 11 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1di9QwFA2yIPgiih87fiwRxLdim7ZJ49s4uiyCK7jusm8haRKn4nSG7Yyrf8Vf671JO0xZYXzwpZRp74Tm3pyctDfnEvJSMi2slQw84FxSMItjzleJET7VRjtvwueCj6f85Lz4cFle7pT6wpywKA8cO-61ZYaZzAAvEL6QrjaZK7n1ADGZdaIMYtupTHcWU4jBMGtjBR6sLAf8HCgkZ8O-uZDchYmkK1TJZFkQIUUpzdt1GFbtaIYKQv6jieomEb2ZTzlSHQ0z1fE9crenmHQaH-0-ueXaB-R3lCnusY0uPZ1jIgxCH6z96Ww-tZ9-ZrSdLS-STFLdWrr4fDqlK5T_T4CKd2v6Q9d1E98eUv1VN8AsafdrsVovg-4rneGmPrQeMrxaOKNn1w6w7Q2d0mh63VhHsS7vFVijuO1Dcn78_svsJOnrMiQ1l3KdVIXzGmiA8KzQvMLtUB6YEwClqIEPVKU03vK0dtbz3PpUmErAmr02sHrSAK75I3LQLlt3SCjjLvcyL7SUDg5MwwGiquDAKpxO0wk57L2iWhgSqLCcC8VyIeBSPrhJ1b2eOZbV-K6GxLVvKrpZoZtVdPOEJFurVdTz2HP_W4yA7b2oxh1-gBhVfYyqfTE6IeUQP2rY8AoQDX_U7Glc_M3OdT3OdCpTHVOpOsMoxyBnWRAwSncteyoVKdI_tPliCHAFSIOfj-AeiETF0LOwPuflhDyOAb_tlrzgMs8rAe2OhsKo38ZX2mYe1MyrkqGs4oS8ioNmZPKuuZiGrt4sNgq5a1E9-R8eeUru4DPHvKRn5GB9tXHPgV2uzVEAkqPw2u8P4fV6ag |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effectiveness+of+heterologous+ChAdOx1+nCoV-19+and+mRNA+prime-boost+vaccination+against+symptomatic+Covid-19+infection+in+Sweden%3A+A+nationwide+cohort+study&rft.jtitle=The+Lancet+regional+health.+Europe&rft.au=Peter+Nordstr%C3%B6m&rft.au=Marcel+Ballin&rft.au=Anna+Nordstr%C3%B6m&rft.date=2021-12-01&rft.pub=Elsevier&rft.issn=2666-7762&rft.eissn=2666-7762&rft.volume=11&rft.spage=100249&rft_id=info:doi/10.1016%2Fj.lanepe.2021.100249&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_d2b2b1b5117f49ecb1e56dfeb11de756 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F26667762%2FS2666776221X00129%2Fcov150h.gif |